FinTech
PharmAust: Completes enrolment of second patient cohort in MND/ALS trial
PharmAust Completes enrolment of second patient cohort in MND/ALS trialPharmAust (PAA) completes the enrolment of the second cohort of patients in its phase...
FinTech
PharmAust: Reports ongoing positive outcomes for canine cancer treatment
PharmAust Reports ongoing positive outcomes for canine cancer treatmentPharmAust (PAA) claims a 12-year-old beagle in its clinical trial for the treatment of canine...
FinTech
PharmAust: Gets approval to increase dosage in MPL trial
PharmAust Gets approval to increase dosage in MPL trialPharmAust (PAA) has received the green light from the trial safety committee to increase the...
FinTech
PharmAust: Receives first $200k instalment for Phase 1 MND trial, appoints trial manager
PharmAust Receives first $200k instalment for Phase 1 MND trial, appoints trial managerClinical-stage biotechnology company PharmAust (PAA) receives over $201,000 under the first...
FinTech
PharmAust: Successfully produces smaller GMP tablets
PharmAust Successfully produces smaller GMP tabletsPharmAust’s (PAA) upcoming human trials receives a major boost as the company’s GMP monepantel (MPL) tablets has been...
FinTech
PharmAust: Completes investigations on COVID-19 infection agent
PharmAust: Completes investigations on COVID-19 infection agentPharmAust (PAA) has investigated the effects of monepantel (MPL) and monepantel sulfone (MPLS) on SARS-CoV2 infection, the...
FinTech
PharmAust: Begins recruiting dogs for canine cancer trial
PharmAust (PAA) has officially started recruiting patients for a second-phase clinical trial testing one of its key drugs against cancer in dogs
The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
